Lexeo Therapeutics, Inc.
LXEO
$4.83
$0.1653.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.86% | -57.46% | -48.11% | -29.67% | -21.16% |
| Total Depreciation and Amortization | 6.19% | 8.28% | 8.63% | 9.62% | 14.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.88% | 151.12% | 248.47% | 230.77% | 218.55% |
| Change in Net Operating Assets | 28.35% | -9.92% | 84.14% | 4,265.78% | 2,100.00% |
| Cash from Operations | -51.02% | -57.17% | -36.40% | -7.51% | -4.95% |
| Capital Expenditure | 59.70% | 1.33% | -318.26% | -726.87% | -12.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -185,692.06% | -134,362.07% | -187,092.00% | 90.15% | 50.00% |
| Cash from Investing | -21,732.40% | -21,767.04% | -56,916.36% | -184.92% | 1.65% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -28.61% | -8.49% | 3.53% | 6.78% | -10.64% |
| Issuance of Common Stock | -55.79% | -93.03% | 1.47% | 247,644.30% | 399,306.12% |
| Repurchase of Common Stock | 69.23% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -107.20% | -14,522.09% | -14,522.09% | -57,736.36% | -- |
| Cash from Financing | -62.26% | -99.93% | -14.47% | 5,092.20% | 62,738.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -207.77% | -221.99% | -295.90% | 307.10% | 312.78% |